Acorda Therapeutics Cdt Stock
Your prediction
Pros and Cons of Acorda Therapeutics Cdt in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acorda Therapeutics Cdt vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Acorda Therapeutics Cdt | - | - | - | - | - | - | - |
| Heron Therapeutics Inc. | 1.880% | 12.739% | 1.659% | -50.864% | -28.501% | -67.883% | -94.618% |
| Evolus Inc | -0.520% | 7.961% | -10.945% | -55.318% | -29.083% | -48.467% | -57.056% |
| Sangamo Therapeutics Inc. | 0.510% | 1.388% | -29.790% | -61.259% | -33.162% | -84.467% | -97.559% |
Comments
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat